AMT in-licenses developmental porphyria drug
Dutch gene therapy firm Amsterdam Molecular Therapeutics BV has obtained an exclusive license to a novel therapeutic agent which is being developed as a treatment for acute intermittent porphyria. The drug, known as AMT-020, was originated in a collaboration between Spanish companies UTE CIMA, Proyecto de Biomedicina CIMA, SL and Digna Biotech, all of which are part of the University of Navarra, in Pamplona, Spain.
AMT explained that the drug is a gene therapy-based product that utilizes adeno-associated viral vector technology for delivery. It is designed to provide a working version of the porphobilinogen deaminase gene to patients who suffer AIP.
The Dutch firm went on to say that the deal follows its successful collaboration with CIMA, which indicated that the agent is safe and has clinical efficacy. Financial terms of the accord were not provided.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze